CN107087409B - 苯并杂环化合物及其应用 - Google Patents

苯并杂环化合物及其应用 Download PDF

Info

Publication number
CN107087409B
CN107087409B CN201580050353.5A CN201580050353A CN107087409B CN 107087409 B CN107087409 B CN 107087409B CN 201580050353 A CN201580050353 A CN 201580050353A CN 107087409 B CN107087409 B CN 107087409B
Authority
CN
China
Prior art keywords
alkyl
compound
agent
cancer
immune checkpoint
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580050353.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN107087409A (zh
Inventor
吕衍达
施增廉
张家鸣
魏采音
刘任伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN107087409A publication Critical patent/CN107087409A/zh
Application granted granted Critical
Publication of CN107087409B publication Critical patent/CN107087409B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
CN201580050353.5A 2014-09-19 2015-09-17 苯并杂环化合物及其应用 Expired - Fee Related CN107087409B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052617P 2014-09-19 2014-09-19
US62/052,617 2014-09-19
PCT/CN2015/089865 WO2016041511A1 (en) 2014-09-19 2015-09-17 Benzo-heterocyclic compounds and their applications

Publications (2)

Publication Number Publication Date
CN107087409A CN107087409A (zh) 2017-08-22
CN107087409B true CN107087409B (zh) 2020-07-31

Family

ID=55532567

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580050353.5A Expired - Fee Related CN107087409B (zh) 2014-09-19 2015-09-17 苯并杂环化合物及其应用

Country Status (8)

Country Link
US (2) US20170283408A1 (enExample)
EP (1) EP3194368B1 (enExample)
JP (2) JP6777638B2 (enExample)
KR (1) KR20170090408A (enExample)
CN (1) CN107087409B (enExample)
AU (1) AU2015317566B2 (enExample)
TW (1) TW201625527A (enExample)
WO (1) WO2016041511A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
AU2016358100B2 (en) 2015-11-19 2021-05-27 Incyte Corporation Heterocyclic compounds as immunomodulators
TW201726623A (zh) 2015-12-17 2017-08-01 英塞特公司 作為免疫調節劑之雜環化合物
TWI850624B (zh) 2015-12-22 2024-08-01 美商英塞特公司 作為免疫調節劑之雜環化合物
TW201808950A (zh) 2016-05-06 2018-03-16 英塞特公司 作為免疫調節劑之雜環化合物
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
DK3472167T3 (da) 2016-06-20 2022-09-05 Incyte Corp Heterocykliske forbindelser som immunomodulatorer
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
IL295660A (en) 2016-12-22 2022-10-01 Incyte Corp Benzooxazole derivatives as immunomodulators
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
RS64055B1 (sr) 2018-03-30 2023-04-28 Incyte Corp Heterociklična jedinjenja kao imunomodulatori
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
EP4219492B1 (en) 2018-05-11 2024-11-27 Incyte Corporation Heterocyclic compounds as immunomodulators
CN108774219B (zh) * 2018-05-17 2021-05-04 中国药科大学 抑制pd-1/pd-l1的小分子化合物及其用途
BR112020026746A2 (pt) 2018-07-13 2021-03-30 Gilead Sciences, Inc. Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição.
CN112955435B (zh) 2018-10-24 2024-09-06 吉利德科学公司 Pd-1/pd-l1抑制剂
KR102211062B1 (ko) 2019-02-27 2021-02-02 충남대학교산학협력단 신규한 나프탈이미드-벤조사이아졸 화합물 및 이를 포함하는 시아나이드 이온 및 트립토판 아미노산의 선택적 검출이 가능한 화학센서
CN109970729B (zh) * 2019-03-12 2024-01-26 西北农林科技大学 一种氟离子探针聚集态荧光增强型染料的合成方法
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
CN110407865B (zh) * 2019-08-02 2022-04-15 山东师范大学 基于苯磺酰胺结构的式（i）化合物及其制备方法与应用
JP7665593B2 (ja) 2019-08-09 2025-04-21 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩
EP4037773A1 (en) 2019-09-30 2022-08-10 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
BR112022009031A2 (pt) 2019-11-11 2022-10-11 Incyte Corp Sais e formas cristalinas de um inibidor de pd-1/pd-l1
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
CA3181538A1 (en) 2020-05-05 2021-11-11 Teon Therapeutics, Inc. Cannabinoid receptor type 2 (cb2) modulators and uses thereof
CN112250682B (zh) * 2020-11-02 2021-12-07 河南大学 一种芳杂环修饰的萘酰亚胺衍生物及其制备方法和用途
EP4240739A1 (en) 2020-11-06 2023-09-13 Incyte Corporation Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
TW202325306A (zh) 2021-09-02 2023-07-01 美商天恩治療有限公司 改良免疫細胞之生長及功能的方法
WO2023081730A1 (en) 2021-11-03 2023-05-11 Teon Therapeutics, Inc. 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
WO2023097211A1 (en) 2021-11-24 2023-06-01 The University Of Southern California Methods for enhancing immune checkpoint inhibitor therapy
US20260015356A1 (en) 2022-07-14 2026-01-15 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
CN115385890B (zh) * 2022-07-19 2023-08-08 杭州庆正鸿科技有限公司 一种1,8萘酰亚胺衍生物及其制备方法与应用
CN117143076A (zh) * 2023-09-01 2023-12-01 河南大学 喹喔啉修饰的萘酰亚胺-多胺缀合物及其制备方法和应用
CN117285546A (zh) * 2023-09-08 2023-12-26 河南大学 咪唑并噻唑修饰的萘酰亚胺-多胺缀合物、制备方法和用途
WO2026035860A1 (en) 2024-08-07 2026-02-12 Teon Therapeutics, Inc. Formulations of adenosine receptor antagonist

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032577A2 (en) * 1998-11-25 2000-06-08 Merck Patent Gmbh Substituted benzo[de]isoquinoline-1,3-diones
WO2008084496A1 (en) * 2007-01-11 2008-07-17 Council Of Scientific & Industrial Research Novel substituted 1h-benz [de] isoquinoline-1, 3 -diones
CN102206203A (zh) * 2011-04-04 2011-10-05 大连理工大学 含有苯并咪唑的萘酰亚胺衍生物的合成及其在抗肿瘤上的应用
CN102731493A (zh) * 2012-07-08 2012-10-17 大连理工大学 一类抗肿瘤含苯并噻唑杂环结构的化合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2423548C2 (de) * 1974-05-15 1984-08-23 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung von 4-Amino1,8-naphthalimid-Verbindungen
DE3942280A1 (de) * 1989-12-21 1991-06-27 Knoll Ag N-substituierte naphthalimide, ihre herstellung und verwendung
CN1857221A (zh) * 2006-04-14 2006-11-08 济南帅华医药科技有限公司 一种同载铂类化合物及其增效剂的抗癌缓释剂
HUP0700433A2 (en) * 2007-06-21 2009-03-30 Avidin Kutato Compounds influencing development or functioning of cellular vesicular systems particularly lipid droplets, pharmaceutical compositions containing these compounds and use them for treatment of illnesses
WO2009089537A2 (en) * 2008-01-11 2009-07-16 Northwestern University Anti-cancer compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032577A2 (en) * 1998-11-25 2000-06-08 Merck Patent Gmbh Substituted benzo[de]isoquinoline-1,3-diones
WO2008084496A1 (en) * 2007-01-11 2008-07-17 Council Of Scientific & Industrial Research Novel substituted 1h-benz [de] isoquinoline-1, 3 -diones
CN102206203A (zh) * 2011-04-04 2011-10-05 大连理工大学 含有苯并咪唑的萘酰亚胺衍生物的合成及其在抗肿瘤上的应用
CN102731493A (zh) * 2012-07-08 2012-10-17 大连理工大学 一类抗肿瘤含苯并噻唑杂环结构的化合物及其应用

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
A TDDFT and PCM-TDDFT studies on absorption spectra of N-substituted 1,8-naphthalimides dyes;Lifen Miao et al.;《Journal of Molecular Structure: THEOCHEM》;20080709;第865卷;第80-81页图1化合物1-19 *
Carbonic anhydrase inhibitors: Synthesis and inhibition of the cytosolic mammalian carbonic anhydrase isoforms I, II and VII with benzene sulfonamides incorporating 4,5,6,7-tetrachlorophthalimide moiety;Kalyan K. Sethi et al.;《Bioorganic & Medicinal Chemistry》;20130626;第21卷;第5171页表3化合物1、4、5，第5173页5.3节 *
Carbonic anhydrase inhibitors: Synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties;Kalyan K. Sethi et al.;《Bioorganic & Medicinal Chemistry》;20140131;第22卷;第1591页表3化合物1、4、5，第1595页6.3节 *
Carbonic anhydrase inhibitors: Synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety;Kalyan K. Sethi et al.;《Bioorganic & Medicinal Chemistry》;20130802;第21卷;第5977页表3化合物1、4、5，第5976页左栏，第5978右栏第4段、第5979页右栏 *
Carbonic anhydrase inhibitory activity of sulfonamides and carboxylic acids incorporating cyclic imide scaffolds;Alaa A.-M. Abdel-Aziz et al.;《Bioorganic & Medicinal Chemistry Letters》;20141002;第24卷;D15第5187页化合物5b、5c、6b、7b、8b *
Discovery of Ligands for ADP-Ribosyltransferases via Docking-Based Virtual Screening;C. David Andersson et al.;《Journal of Medicinal Chemistry》;20120723;第55卷(第17期);第7710页表1化合物4 *
Novel naphthalimide derivatives as potential apoptosis-inducing agents: Design, synthesis and biological evaluation;Aibin Wu et al.;《European Journal of Medicinal Chemistry》;20090716;第44卷;4675页图1化合物1、第4676页图2化合物4、6 *
Novel Naphthalimide–Benzoic Acid Conjugates as Potential Apoptosis-Inducing Agents: Design, Synthesis, and Biological Activity;Aibin Wu et al.;《Chem Biol Drug Des》;20111231;第78卷;第942页化合物1、第943页化合物7、8 *
Phthalonimides (1,3,4-Trioxo-1,2,3,4-tetrahydroisoquinolines) of Potential Biological Interest;N.P.Buu-Hoi et al.;《Journal of Heterocyclic Chemistry》;19680831;第5卷(第4期);第545页化合物III、表1前5个化合物 *
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer;Julie R.Brahmer et al.;《 The New England Journal of Medicine》;20120628;第366卷;第2456页左栏最后1段 *
Synthesis and fluorescence property of some novel 1,8-naphthalimide derivatives containing a thiophene ring at the C-4 position;Jin Zhengneng et al.;《Dyes and Pigments》;20120801;第96卷;第206页式1化合物1，第207页表3化合物2a-2i *
The heterocyclic ring of 4-Substituted-1,8-naphthalimides is not inert to nucleophilic attack,Contrary to earlier reports;Ryan K. McKenney et al.;《Organic & Biomolecular Chemistry》;20130521;第11卷(第26期);第4391页图1-2、第4394页化合物12-13 *

Also Published As

Publication number Publication date
EP3194368B1 (en) 2020-12-23
US20200339557A1 (en) 2020-10-29
EP3194368A4 (en) 2018-03-21
JP2017528524A (ja) 2017-09-28
TW201625527A (zh) 2016-07-16
CN107087409A (zh) 2017-08-22
US20170283408A1 (en) 2017-10-05
KR20170090408A (ko) 2017-08-07
JP6777638B2 (ja) 2020-10-28
AU2015317566B2 (en) 2019-10-10
EP3194368A1 (en) 2017-07-26
AU2015317566A1 (en) 2017-04-06
WO2016041511A1 (en) 2016-03-24
JP2021008502A (ja) 2021-01-28

Similar Documents

Publication Publication Date Title
CN107087409B (zh) 苯并杂环化合物及其应用
JP4560483B2 (ja) 血管静態化物質およびそれらの使用法
JP2013107903A (ja) 化学療法の強化方法
WO2021262484A1 (en) Combination therapy for treatment of cancer
JP4930055B2 (ja) 抗腫瘍剤
CN104968358B (zh) 涉及粘液素的疾病治疗
WO2022201063A1 (en) Nanoparticle composition for targeted protein degradation
PT1827437E (pt) Combinação de agentes terapêuticos para o tratamento do cancro
CN108025013A (zh) 用于治疗骨髓瘤的赛度替尼
TW200803842A (en) Antineoplastic combinations of temsirolimus and sunitinib malate
JP2017523178A (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤
KR20160106042A (ko) 암 치료용 약학적 배합물
JP2009517403A (ja) Ｐａｒｐ−１阻害剤の使用
CN111643502A (zh) 喹啉衍生物联合化疗药物用于治疗非小细胞肺癌
US20210128683A1 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
US9872882B2 (en) Aurantiamide dipeptide derivatives for treatment or prevention of angiogenesis-related diseases
TW202404600A (zh) 使用ptpn11抑制劑及pd-1/pd-l1抑制劑之組合療法
WO2025059081A1 (en) Bicyclic compounds for restoring mutant p53 function
AU2021200121A1 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
HK40091747A (zh) 用於治疗癌症的组合疗法
JP2024516848A (ja) 血液がんを処置する方法
JP2022547554A (ja) 癌を処置する方法
JP2022543021A (ja) がんを処置する方法及び使用
WO2020205608A1 (en) Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto
HK1211213B (en) Treatment of diseases involving mucin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200731

Termination date: 20210917